TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05113264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 'Penny' via Memora Platform
Description: The overall objective of this study is to evaluate the feasibility and safety of a novel SMS text- based intervention of an Algorithmically Driven Augmented Intelligence chatbot, Penny. This chat bot will walk patients through how and when to take their oral chemotherapies, as well as provide real-time management of side effects Grade II or less, and escalate to the clinical team side effects of Grade III or more, as based on the Common Terminology Criteria for Adverse Events (CTCAE), for patients that have a gastrointestinal (GI) cancer.
Study: NCT05830266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful with your Baby group-based therapist-guided intervention
Description: This 8-sessions long intervention is one of very few interventions that actively includes the baby in the therapy sessions. The intervention includes the following sessions: Becoming aware of the autopilot, Practice to really look at your baby, Getting back in touch with yourself, Responding sensitively to your baby, Taking care of yourself in the difficult moments, Distance and proximity: it's both part of it, Dealing with expectations of yourself and the environment and Mindful parenting: trial and error. The intervention is a group-based therapist-guided intervention via a video-conferencing tool (e.g., Zoom).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindful with your baby self-guided online intervention
Description: This 8-sessions long intervention includes the following sessions: Autopilot, Fresh view, At home in your body, Responsive versus reactive parenting, Kindness to yourself, Distance and proximity, Boundaries and taking care of yourself and Mindful parenting - day by day. The intervention is an individual self-guided online intervention.
Study: NCT06487052

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard Catheter-Directed Low Dose Thrombolysis
Description: Using femoral or jugular vein access the mechanical blood clots fragmentation by PigTail 6F catheter circular rotational movements. For unilateral thromboembolism, the PigTail catheter is positioned in the obstructed branch of the pulmonary artery, 1 mg of alteplase is injected as a bolus, followed by a micro-jet injection of 1 mg/hour. For bilateral thromboembolism, the PigTail catheter is positioned in the pulmonary trunk with a bolus of 2 mg alteplase followed by an infusion of 2 mg/hour. The total duration of infusion will be 9 hours, the total dose of alteplase will be 10 mg for unilateral lesions and 20 mg for bilateral lesions. During the alteplase infusion, unfractionated heparin is continued with a target activated partial thromboplastin time (aPTT) of 50 to 60 seconds. After completion of the procedure, UFH therapy is continued for 24 hours, followed by a change to oral anticoagulants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Anticoagulation
Description: Therapy with UFH with targeted аPTT lasts for 24 hours (no more than 48 hours in total). Then the change to oral anticoagulants is performed
Study: NCT05617560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedical care
Description: Telemedical care will be provided to all participants after stationary hospital stay. This care will be in form of telephone consultations and / or videocall consultations with a medical physician. Depending on the individual medical history and the planned aftercare and procedure of the participants it will comprise of one or more such telephone consultations.
Study: NCT05363007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: Upfront SI (Arm A): Upfront nanoliposomal irinotecan (80 mg/m2, day 1) + 5-FU/leucovorin (2400 mg/m2, 400 mg/m2) plus SI~Add-on SI (Arm B): Add-on SI following limited progression to prior nanoliposomal irinotecan (last dose used) + 5-FU/leucovorin (last dose used)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: Upfront SI (Arm A): Upfront nanoliposomal irinotecan (80 mg/m2, day 1) + 5-FU/leucovorin (2400 mg/m2, 400 mg/m2) plus SI~Add-on SI (Arm B): Add-on SI following limited progression to prior nanoliposomal irinotecan (last dose used) + 5-FU/leucovorin (last dose used)
Study: NCT05702268

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICP-332 Placebo
Description: Tablets, in appearance, size, color, dosage form, packaging, instructions, labels and other aspects of the corresponding specifications of ICP-332.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-332 Placebo
Description: Tablets, in appearance, size, color, dosage form, packaging, instructions, labels and other aspects of the corresponding specifications of ICP-332.
Study: NCT06104293

Intervention type: OTHER
Group type: OTHER
Intervention: Grass Pollen Allergen Exposure
Description: After the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3).~Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations.
Study: NCT05363007

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: spleen irradiation
Description: Upfront SI (Arm A): upfront spleen irradiation (1 Gy/fx, day 1-4) in cycle 2~Add-on SI (Arm B): add-on spleen irradiation (1 Gy/fx, day 1-4) in cycle 1 following limited progression to prior nanoliposomal irinotecan + 5-FU/leucovorin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: spleen irradiation
Description: Upfront SI (Arm A): upfront spleen irradiation (1 Gy/fx, day 1-4) in cycle 2~Add-on SI (Arm B): add-on spleen irradiation (1 Gy/fx, day 1-4) in cycle 1 following limited progression to prior nanoliposomal irinotecan + 5-FU/leucovorin
Study: NCT05305716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Pilates Training
Description: The group that received telerehabilitation and telerehabilitation-based pilates training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The group who received breathing and relaxation exercises with a home program.
Study: NCT06642480

Intervention type: DRUG
Group type: OTHER
Intervention: Post Operative Analgesia
Description: administering 100 mg of intravenous tramadol 30 minutes before the operation is completed

Intervention type: DRUG
Group type: OTHER
Intervention: Post Operative Analgesia
Description: VAS of 63 patients was determined by injecting tramadol at a dose of 100 mg 30 minutes before the operation was completed. It was observed in the recovery room at 30, 60, and 120 minutes.
Study: NCT05910827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-001
Description: HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-001
Description: HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-001
Description: HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks
Study: NCT06104293

Intervention type: OTHER
Group type: OTHER
Intervention: Grass Pollen Allergen Exposure
Description: After the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3).~Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations.

Intervention type: OTHER
Group type: OTHER
Intervention: Grass Pollen Allergen Exposure
Description: After the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3).~Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations.
Study: NCT05665647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: SIM0417/ritonavir and itraconazole
Description: SIM0417/Ritonavir: Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1-Day2, Day9-Day10, BID; Day3,Day11(once only in the morning); Itraconazole：Dose: 200mg once；Day6-Day13, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: SIM0417/ritonavir and rifampicin
Description: SIM0417/Ritonavir:Dose: 750 mg SIM0417 coadministered with 100 mg ritonavir once: Day1,Day11(once only in the morning); Rifampicin：Dose: 0.6g once; Day4-Day12, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3: SIM0417/ritonavir and midazolam
Description: SIM0417/Ritonavir: 750 mg SIM0417 coadministered with 100 mg ritonavir, Day3-Day6, BID; Day7(once only in the morning) Midazolam：Dose: 2mg once; Day1, Day6, QD
Study: NCT06157424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thread Embedding Acupuncture
Description: Thread Embedding Acupuncture is applied at acupoints including CV-12, CV-13, ST-36, PC-6, BL-17, BL-18, BL-21 on both sides of the body every 2 weeks, totaling 2 sessions over 4 weeks of intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture is administered using adhesive patches with small needles (0.25 x 1.3 mm) placed at acupoints TF4, AH6, CO12, CO4, CO2 once a week, totaling 4 sessions over the 4-week intervention period.
Study: NCT05910827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
Study: NCT05041101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grapiprant
Description: Given PO
Study: NCT05817045

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RD-X19
Description: Investigational device that uses safe electromagnetic energy to target the oropharynx.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
Study: NCT06334939

Intervention type: DEVICE
Intervention: Bispectral Index Monitoring
Description: Study patients will undergo perioperative bispectral index and BIS suppression ratio (SR) monitoring under anesthesia. The lowest BIS and BIS SR values and the values taken at 10-minute intervals will be recorded throughout the case.~The Richmond agitation scale will be calculated in the recovery room after anesthesia.

Intervention type: DEVICE
Intervention: Bispectral Index Monitoring
Description: Study patients will undergo perioperative bispectral index and BIS suppression ratio (SR) monitoring under anesthesia. The lowest BIS and BIS SR values and the values taken at 10-minute intervals will be recorded throughout the case.~The Richmond agitation scale will be calculated in the recovery room after anesthesia.
Study: NCT05036278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
Description: Dosage Levels:~* 40 IU/kg/dose two times per week~* 50 IU/kg/dose every 5 days~* 60 IU/kg/dose, Less frequent dosing (e.g. every 7 days), the total recommended maximum dose/infusion is 6000 IU.
Study: NCT05507424

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone Positioning
Description: Newborn will be prone position for 30-60 seconds during delayed umbilical cord clamping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supine Positioning
Description: Newborn will be supine position for 30-60 seconds during delayed umbilical cord clamping
Study: NCT06157424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of proton pump inhibitors, additional antacids as needed, and lifestyle modifications.
Study: NCT06008808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is provided by Incyte Corporation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is provided by Incyte Corporation.
Study: NCT05652855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHB088C for Injection
Description: MHB088C for Injection, an antibody drug-conjugated molecule (ADC)
Study: NCT05148624

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embryo transfer
Description: immediate ambulation after embryo transfer
Study: NCT05146908

Intervention type: BIOLOGICAL
Intervention: 2 Blood samples from arterial and/or central venous catheters
Description: 5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
Study: NCT05148624

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: embryo transfer
Description: immediate ambulation after embryo transfer
Study: NCT06161753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy
Description: CFT is an individualised, combined physical and behavioural approach specifically developed to target the multidimensional complexity of persistent LBP. CFT utilises a multidimensional clinical reasoning framework that enables the clinician to identify both modifiable and non-modifiable biopsychosocial factors (i.e. physical, cognitive, emotional, social, lifestyle and health comorbidities) underlying an individual's LBP. CFT targets these factors by: (1) helping the patient 'make sense of their pain' from a biopsychosocial perspective, (2) build confidence to engage in valued activities through functional movement training and (3) adopt positive lifestyle behaviours (O'Sullivan et al., 2018).~Participants will receive approximately 7 treatment sessions over a 13-week period, although this will vary depending on participant needs, in line with the individualised nature of the intervention. Participants will be provided a booster session at 26 weeks to reinforce self-management.
Study: NCT06548685

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Grafting
Description: Bone grafting in some sites and Vegetable Ivory Grafting in Parallel sites

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Grafting
Description: Bone grafting in some sites and Vegetable Ivory Grafting in Parallel sites

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Grafting
Description: Bone grafting in some sites and Vegetable Ivory Grafting in Parallel sites

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Grafting
Description: Bone grafting in some sites and Vegetable Ivory Grafting in Parallel sites

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone Grafting
Description: Bone grafting in some sites and Vegetable Ivory Grafting in Parallel sites

Intervention type: OTHER
Group type: OTHER
Intervention: Vegetable Derived
Description: Tooth extraction followed by socket preservation with vegetable ivory

Intervention type: OTHER
Group type: OTHER
Intervention: Vegetable Derived
Description: Tooth extraction followed by socket preservation with vegetable ivory

Intervention type: OTHER
Group type: OTHER
Intervention: Vegetable Derived
Description: Tooth extraction followed by socket preservation with vegetable ivory

Intervention type: OTHER
Group type: OTHER
Intervention: Vegetable Derived
Description: Tooth extraction followed by socket preservation with vegetable ivory

Intervention type: OTHER
Group type: OTHER
Intervention: Vegetable Derived
Description: Tooth extraction followed by socket preservation with vegetable ivory
Study: NCT06632496

Intervention type: DEVICE
Intervention: BD Prevue(TM) II
Description: Ultrasound-guided peripheral intravenous catheter placement procedure using the BD Prevue(TM) II
Study: NCT05457998

Intervention type: DIAGNOSTIC_TEST
Intervention: Flutemetamol F18 Injection
Description: PET imaging of Abeta amyloid

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]-RO6958948 Injection
Description: PET imaging of Tau aggregates

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]-RO6958948 Injection
Description: PET imaging of Tau aggregates

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]-MK-6240 Injection
Description: PET imaging of Tau aggregates
Study: NCT05146908

Intervention type: OTHER
Intervention: Echography
Description: In 3 steps:~* before initiation of enteral nutrition~* 4h after initiation of enteral nutrition~* After 24 hours of enteral nutrition
Study: NCT04953884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: wilate
Description: wilate is a plasma-derived, stable, highly purified, double virus inactivated concentrate of freeze-dried active VWF and factor VIII (FVIII) prepared from cryoprecipitate and intended for the treatment of patients with von Willebrand disease (VWD) and/or haemophilia A
Study: NCT04838626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]CTT1057
Description: PET/CT imaging with \[18F\]CTT1057
Study: NCT05146908

Intervention type: OTHER
Intervention: Data collection
Description: At inclusion:~Calculation of severity scores; collection of reason for admission and demographic data; main comorbidities and treatments administered; the time between admission and nutritional recovery; risk factors for gastroparesis; current organ failure and supplements. Presence of parenteral nutrition, ongoing carbohydrate intake. Caloric objective.~Within the first 24 hours, collection of:~* echographic parameters at H0, H4 and H24~* venous congestion parameters~* biological parameters within 24 hours Constitution of a biobank (at H0 and H24)~Within the first 7 days, collection of:~* the occurrence or not of the primary endpoint (and time to occurrence).~* symptoms of gastrointestinal dysfunction~Within 30 days, collection of:~* organ failure and replacement over the period, and mortality.~* the occurrence or not of ventilator-associated lung disease (VAPD). Each patient is followed for 30 days. Survival will be assessed at 30 days before discharge from the study.
Study: NCT05443126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0031
Description: EP0031 is a potent next-generation selective RET-inhibitor (SRI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0031
Description: EP0031 is a potent next-generation selective RET-inhibitor (SRI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0031
Description: EP0031 is a potent next-generation selective RET-inhibitor (SRI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0031
Description: EP0031 is a potent next-generation selective RET-inhibitor (SRI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0031
Description: EP0031 is a potent next-generation selective RET-inhibitor (SRI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0031
Description: EP0031 is a potent next-generation selective RET-inhibitor (SRI)
Study: NCT06101290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablative local therapy
Description: Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
Study: NCT03498014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic analysis allowing personalized opioid prescription
Description: Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard opioid prescription
Description: Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)
Study: NCT04373603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: sodium chloride and water for use as control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid
Description: Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
Study: NCT05596214

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Curcumin-Berberine (coptis)
Description: dietary supplement

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05137938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine (IN)
Description: A sterile form of ketamine will be administered intranasally twice weekly for four weeks. Dosing schedule will be determined based on patient's weight using a specialized formula. Patients will be started at the lowest dose during the first treatment session. Dose will be titrated further to therapeutic dose in the following sessions. The dose will be adjusted if patients do not tolerate full therapeutic doses. After receiving the second treatment of each week, participants will be seen by a study physician to determine dosing for the following week. Patients will be monitored by trained personnel for the full duration of the 2 hour supervision period. Vital signs and physical symptoms will be monitored consistently and measurements taken every 30 minutes. Appropriate medications will be provided to manage treatment-related side effects and any adverse events. Labetalol will be used in the management of treatment-related transient hypertension as needed.